Jose M. Rubio, MD, PhD

  • 8Articles
  • 48.2KReads
  • 2013–2025Active
  • 18Collaborators
  • 300Citations

About

Jose M. Rubio, MD, PhD, is affiliated with the Department of Psychiatry at Zucker Hillside Hospital, the Institute of Behavioral Science at Feinstein Institutes of Medical Research, and Northwell Health. Rubio has published extensively on schizophrenia and schizoaffective disorders, focusing on topics such as clozapine monitoring, long-acting injectable antipsychotic agents, and neuroleptic malignant syndrome. His work also addresses the duration and impact of untreated psychiatric disorders and quality of life following remission of mental illnesses. Rubio’s research has appeared in Psychiatrist.com from 2013 to 2025.

Publications

JCP
Clozapine Monitoring in the Post-REMS World: Some Guidance for Clinicians
ASCP Corner

Clozapine Monitoring in the Post-REMS World: Some Guidance for Clinicians

May 5, 2025

While the abolition of REMS for clozapine expands access, the change could create confusion. Among the most relevant examples are mismatches between FDA recommendations for lifetime monitoring and the...
,
JCP
LAI Implementation After Schizophrenia Diagnosis
Original Research

LAI Implementation After Schizophrenia Diagnosis

April 19, 2023

Although long-acting injectable antipsychotic agents (LAIs) are effective in preventing relapse, their use in first-episode schizophrenia was low, and LAIs were rarely the first therapy for early-phase schizophrenia.
, , , et al
JCP
Predictors for Initiation of LAIs in Individuals With Early-Phase Schizophrenia
Original Research

Predictors for Initiation of LAIs in Individuals With Early-Phase Schizophrenia

February 13, 2023

Initiation of LAIs was predicted by greater switching of oral antipsychotics and more ED visits. LAIs are often used to respond to relapse rather than prevent it.
, , , et al
JCP
ASCP Corner

How to Make an Effective Offer of Clozapine

November 30, 2021

This ASCP Corner article discusses how to identify treatment-resistant patients who would benefit from clozapine and then offers tips on how to start the treatment conversation with these patients.
,
JCP
Review Article

Outcomes of NMS With Depot Versus Oral Antipsychotics

November 24, 2020

Is the advantage of longer-term medication release with long-acting injectable antipsychotics offset by an increased risk of more prolonged and severe neuroleptic malignant syndrome? This systematic review and pooled...
, , , et al
JCP
ASCP Corner

Nonpsychotic Psychiatric Disorders and Substance Use Disorders

April 26, 2017

This month's ASCP Corner discusses the significant problem of untreated psychiatric disorders and substance use disorders. The authors review the association between untreated illness and morbidity/mortality, look at ways...
,
JCP
ASCP Corner

Duration and Relevance of Untreated Psychiatric Disorders, 1: Psychotic Disorders

March 29, 2017

This month's ASCP Corner discusses the significant problem of untreated psychosis. The authors review the factors that contribute to a longer time to treatment, the impact of untreated psychosis,...
,
JCP
Original Research

Quality of Life Following Remission of Mental Disorders: Findings From the National Epidemiologic Survey on Alcohol and Related Conditions

May 15, 2013

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe